



## **Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference**

June 1, 2021

HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals, Ltd.](https://www.kiniksa.com) (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 9:40 a.m. Eastern Time.

A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at [www.kiniksa.com](https://www.kiniksa.com). A replay of the webcast will be available on Kiniksa's website for 14 days following the conference.

### **About Kiniksa**

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of assets, ARCALYST<sup>®</sup> (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit [www.kiniksa.com](https://www.kiniksa.com).

ARCALYST<sup>®</sup> is a registered trademark of Regeneron Pharmaceuticals, Inc.

***Every Second Counts!***<sup>™</sup>

### **Kiniksa Investor and Media Contact**

Rachel Frank  
(339) 970-9437  
[rfrank@kiniksa.com](mailto:rfrank@kiniksa.com)



Source: Kiniksa Pharmaceuticals, Ltd.